Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2024-2030

Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2024-2030


The Immuno-oncology Clinical Trials Market size was estimated at USD 6.13 billion in 2023 and expected to reach USD 6.58 billion in 2024, at a CAGR 11.17% to reach USD 12.87 billion by 2030.

Global Immuno-oncology Clinical Trials Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immuno-oncology Clinical Trials Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immuno-oncology Clinical Trials Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immuno-oncology Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Exscientia PLC, F. Hoffmann-La Roche Ltd., ICON PLC, IO Biotech ApS, IQVIA Inc., Laboratory Corporation of America Holdings, Medpace, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Rubius Therapeutics, Inc., and Syneos Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-oncology Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

Design
Expanded Access Trials

Interventional Trials

Observational Trials

Phase
Phase I

Phase II

Phase III

Phase IV

Indication
Hematological Cancer

Solid Tumors

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immuno-oncology Clinical Trials Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immuno-oncology Clinical Trials Market?
3. What are the technology trends and regulatory frameworks in the Immuno-oncology Clinical Trials Market?
4. What is the market share of the leading vendors in the Immuno-oncology Clinical Trials Market?
5. Which modes and strategic moves are suitable for entering the Immuno-oncology Clinical Trials Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Immuno-oncology Clinical Trials Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of cancer and the growing adoption of targeted therapy
5.1.1.2. Growing significance of companion diagnostics in drug development
5.1.1.3. Rapidly increasing demand for personalized medicine
5.1.2. Restraints
5.1.2.1. Requirement of high capital investments and low cost-benefit ratio
5.1.3. Opportunities
5.1.3.1. Advancements in immuno-oncology testing
5.1.3.2. Increasing financial support from the government for cancer R&D
5.1.4. Challenges
5.1.4.1. Huge complexity in the production and manufacturing processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Immuno-oncology Clinical Trials Market, by Design
6.1. Introduction
6.2. Expanded Access Trials
6.3. Interventional Trials
6.4. Observational Trials
7. Immuno-oncology Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
8. Immuno-oncology Clinical Trials Market, by Indication
8.1. Introduction
8.2. Hematological Cancer
8.3. Solid Tumors
9. Americas Immuno-oncology Clinical Trials Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immuno-oncology Clinical Trials Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.
10. South Korea
10.
11. Taiwan
10.
12. Thailand
10.
13. Vietnam
11. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.
10. Nigeria
11.
11. Norway
11.
12. Poland
11.
13. Qatar
11.
14. Russia
11.
15. Saudi Arabia
11.
16. South Africa
11.
17. Spain
11.
18. Sweden
11.
19. Switzerland
11.
20. Turkey
11.
21. United Arab Emirates
11.
22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AstraZeneca PLC
13.1.2. BioNTech SE
13.1.3. Bristol Myers Squibb Company
13.1.4. Exscientia PLC
13.1.5. F. Hoffmann-La Roche Ltd.
13.1.6. ICON PLC
13.1.7. IO Biotech ApS
13.1.8. IQVIA Inc.
13.1.9. Laboratory Corporation of America Holdings
13.1.
10. Medpace, Inc.
13.1.
11. Merck KGaA
13.1.
12. Novartis AG
13.1.
13. Pfizer Inc.
13.1.
14. Rubius Therapeutics, Inc.
13.1.
15. Syneos Health, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
FIGURE 3. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET DYNAMICS
FIGURE 7. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
FIGURE 8. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 10. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings